<HTML>

<HEAD>
<TITLE>
  Pacific Neuropsychiatric Institute: 
  Depression Related Lectures
</TITLE>

<LINK REL="stylesheet" TYPE="text/css" HREF="/.styles/main.css">
</HEAD>

<BODY BGCOLOR="white">

<ILAYER SRC="/.clip/top.html"></ILAYER>

<TABLE BORDER=0 WIDTH="100%">
  <TR VALIGN="top">
    <TD ALIGN="left">
      <A HREF="http://www.pni.org/about_pni.html"><IMG SRC="http://www.pni.org/.pictures/pni_banner_small.jpg" ALT="PNI" BORDER=0></A>
    </TD>

    <TD ALIGN="right">
    </TD>
  </TR>
</TABLE>


<H1>Depression Related Lectures</H1>

<P>
Vernon M Neppe MD, PhD, FFPsych(SA), FRCPC
</P>

<H2>Combination serotonin antidepressant therapy</H2>

<OL>
  <LI>
    The development of a broader theory of innovative 
    psychopharmacotherapy and the understanding of 
    concepts such as neuromodulation and partial agonism.
  </LI>

  <LI>
    To discuss the clinical and theoretical frameworks 
    for enhancing the effects of SSRIs in cases of 
    clinical refractoriness and side-effects.
  </LI>
</OL>

<H2>Antidepressants, serotonin specificity and neuromodulation</H2>

<OL>
  <LI>
    The development of a broader understanding of why 
    antidepressants succeed and fail when they do and what 
    to do about it.
  </LI>

  <LI>
    To educate in the area of serotonin in the context 
    of clinical psychiatry.
  </LI>

  <LI>
    To evaluate the serotonin 2 receptor with regard 
    to management options and problems.
  </LI>

  <LI>
    To elucidate a role for norepinephrine in relation to 
    serotonin and depression.
  </LI>

  <LI>
    To establish alternatives for lowering antidepressant 
    side effects.
  </LI>

  <LI>
    To develop a profile of the ideal antidepressant 
    compound based on a pharmacologic model.
  </LI>
</OL>

<H2>
  Modern frameworks for the management of depression: the 
  new antidepressants
</H2>

<OL>
  <LI>
    To educate in the area of depression and anxiety and to 
    demonstrate areas of similarity and differences.
  </LI>

  <LI>
    To discuss the clinical implications with regard to 
    management options and problems.
  </LI>

  <LI>
    The development of a broader theory of innovative 
    psychopharmacotherapy and the understanding of concepts 
    such as neuromodulation and partial agonism.
  </LI>

  <LI>
    To educate in the area of serotonin re-uptake inhibition 
    and the partial agonists in the domain of the clinical 
    psychiatric context.
  </LI>

  <LI>
    To discuss the clinical and theoretical frameworks for 
    enhancing the effects of SSRIs in cases of clinical 
    refractoriness and side-effects.
  </LI>

  <LI>
    To develop a profile of the ideal antidepressant 
    compound based on a pharmacologic model.
  </LI>
</OL>


<H2>
  Innovations in the management of anxiety and depression 
  in the female patient
</H2>

<OL>
  <LI>
    To educate in the area of anxiety and depression and 
    to demonstrate areas of similarity and differences.
  </LI>

  <LI>
    To discuss the clinical implications with regard to 
    management options and problems.
  </LI>

  <LI>
    The development of a broader theory of innovative 
    psychopharmacotherapy and the understanding of 
    concepts such as neuromodulation using the bathtub 
    analogy and partial agonism.
  </LI>

  <LI>
    To discuss the clinical and theoretical frameworks 
    for enhancing the effects of antidepressants in cases 
    of clinical refractoriness and side-effects.
  </LI>

  <LI>
    To focus these theories on the female patient with 
    consideration of premenstrual, pregnancy, post-partum 
    situations and the post-menopausal frameworks.
  </LI>
</OL>


<H2>
  Antidepressants choosing, resistance, switching, 
  combinations: the rest of the picture
</H2>

<OL>
  <LI>
    The development of a broader understanding of 
    chemical reasons underlying antidepressant response 
    and side-effects
  </LI>

  <LI>
    To educate in the area of serotonin and norepinephrine 
    in the context of clinical psychiatry.
  </LI>

  <LI>
    Examination of serotonin subtypes with regard to 
    management options and problems.
  </LI>

  <LI>
    To elucidate a role for norepinephrine in relation to 
    serotonin and depression.
  </LI>

  <LI>
    To establish alternatives for lowering antidepressant 
    side effects.
  </LI>

  <LI>
    To develop a profile of the ideal antidepressant 
    compound based on a pharmacologic model.
  </LI>

  <LI>
    To discuss models of shifting from SSRI therapy.
  </LI>
</OL>


<H2>Insomnia, Psychiatric Disturbance and Antidepressants</H2>

<OL>
  <LI>To educate in the area of sleep and insomnia</LI>

  <LI>
    To discuss the clinical implications with regard to 
    management options and problems linked with psychiatry.
  </LI>

  <LI>
    The development of a broader theory of innovative 
    psychopharmacotherapy and the understanding of 
    concepts such as receptor complexes
  </LI>

  <LI>
    To educate in the nonpharmacologic management of insomnia.
  </LI>

  <LI>
    To discuss the clinical and theoretical frameworks for the 
    current hypnotic agents and antidepressants.
  </LI>
</OL>


<H2>Hepatopsychiatry and antidepressants: P 450 and beyond</H2>

<OL>
  <LI>To detail the pharmacology of the P450 cytochrome system.</LI>

  <LI>
    Discuss the relevance of antidepressants and drug 
    interactions.
  </LI>
</OL>


<H2>
  Serotonin neurotransmission: Implications for depression, 
  anxiety and irritability
</H2>

<OL>
  <LI>
    The development of a broader understanding of why 
    antidepressants succeed and fail when they do and 
    what to do about it.
  </LI>

  <LI>
    To educate in the area of serotonin in the context 
    of clinical psychiatry.
  </LI>

  <LI>
    To evaluate the serotonin 2 receptor with regard to 
    management options and problems.
  </LI>

  <LI>
    To elucidate a role for norepinephrine in relation 
    to serotonin and depression, anxiety and irritability.
  </LI>

  <LI>
    To develop a profile for treatement based on a 
    pharmacologic model.
  </LI>
</OL>

<H2>Pharmacologic management of anxiety with depression</H2>

<OL>
  <LI>
    To educate in the area of anxiety and depression overlap.
  </LI>

  <LI>
    To discuss the clinical implications with regard to 
    management options and problems.
  </LI>

  <LI>
    To discuss the role of neuromodulation in the brain and 
    explanation of apparent paradoxes.
  </LI>
</OL>


<H2>The new antidepressants: a perspective</H2>

<OL>
  <LI>
    A broader understanding of chemical reasons underlying 
    antidepressant response and side-effects.
  </LI>

  <LI>
    To educate in the area of serotonin and norepinephrine 
    in the context of clinical psychiatry.
  </LI>

  <LI>
    Examination of  serotonin subtypes with regard to 
    management options and problems.
  </LI>

  <LI>
    To elucidate a role for norepinephrine in relation 
    to serotonin and depression.
  </LI>

  <LI>
    To establish alternatives for lowering antidepressant 
    side effects in the post - SSRI era
  </LI>

  <LI>
    To develop a profile of the ideal antidepressant compound 
    based on a pharmacologic model.
  </LI>
</OL>


<H2>
  Perspectives to the depressed medically ill / geriatric 
  patient with depression
</H2>

<OL>
  <LI>
    To evaluate problems of anxiety, depression and combinations 
    in the older patient
  </LI>

  <LI>
    To elucidate a role for norepinephrine in relation to 
    serotonin and depression.
  </LI>

  <LI>
    To establish alternatives for lowering antidepressant 
    side effects.
  </LI>

  <LI>
    To develop a profile of the ideal antidepressant compound 
    based on a pharmacologic model.
  </LI>
</OL>

<ILAYER SRC="/.clip/bottom.html"></ILAYER>

<A HREF="./"><IMG SRC="http://www.pni.org/.pictures/arrow_back_t_28x22.gif" BORDER=0 ALT="BACK" WIDTH=28 HEIGHT=22></A>

<A NAME="copyright"></A>
<P>
<FONT SIZE="-2">
&#169; Copyright 1997 Pacific Neuropsychiatric Institute. 
</FONT>
</P>

</BODY>

</HTML>
